Ibogaine CYP2D6 Metabolism: Why Genetics and Inhibitors Matter

Definition box

Definition: Ibogaine CYP2D6 metabolism refers to the major role of cytochrome P450 2D6 in O-demethylating ibogaine to noribogaine (12-hydroxyibogamine). Genetic poor metabolizers and people taking strong CYP2D6 inhibitors can show substantially different exposure—relevant to QTc/safety discussions. Physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) still requires cardiac screening and monitoring; metabolism literacy does not create a DIY dosing calculator. Evidence gap: Key human PK papers (Obach; Glue et al.; later OUD PK/PD) primarily describe oral dosing contexts. Cherian/MISTIC = oral ibogaine + IV magnesium—not IV-ibogaine PK proof. U.S. Schedule I / not FDA-approved. Provisional Mexico programs ≠ FDA/US clinics. No cure claims. No DIY dosing.

Quotable answer (53 words)

Ibogaine is largely converted to noribogaine via CYP2D6; poor metabolizers and CYP2D6 inhibitors can raise exposure. That variability matters for QTc risk discussions. IV ibogaine infusion still needs physician supervision and monitoring; most published PK evidence is oral-route. Not a DIY genotype dosing guide. Not FDA-approved.

The core biochemistry (plain language)

1. Ibogaine enters the body (literature PK is mostly oral).
2. CYP2D6 catalyzes O-demethylation to noribogaine (Obach et al.).
3. Noribogaine can persist and is pharmacologically active in its own right.
4. People differ in CYP2D6 activity because of genetics and interacting drugs.
5. Higher or prolonged active exposure is part of why cardiac monitoring culture exists.

Noribogaine explainers: /blog/noribogaine-explained · /blog/noribogaine-trials-vs-iv-infusion.

What Glue et al. taught (oral, controlled PK framing)

Glue et al. (*Journal of Clinical Pharmacology*) studied a single oral 20 mg ibogaine dose in healthy volunteers pretreated with placebo or the CYP2D6 inhibitor paroxetine. Reduced CYP2D6 activity markedly altered ibogaine kinetics and increased exposure to the combined active moiety (ibogaine + noribogaine). Authors discussed prudence around genotyping and dose individualization concepts in research settings—not a consumer microdosing chart.

This site will not convert that paper into milligram recipes.

What later OUD PK/PD work adds (still oral-context teaching)

Open-label/oral treatment-dose research in opioid use disorder cohorts has linked CYP2D6 activity scores to ibogaine clearance and examined concentration–QTc relationships (see Knuijver safety cohort lineage and related PK/PD analyses). Teaching themes commonly emphasized in that literature:

• Large interindividual variability
• Clearance strongly related to CYP2D6 activity
• QTc signals associated with exposure discussions
• Interest in individualized approaches inside clinical research—not DIY

Knuijver et al. (*Addiction*, 2021) remains a primary oral QTc teaching anchor.

Interactions hub: /blog/ibogaine-drug-interactions-qtc.

Poor metabolizers, intermediate metabolizers, inhibitors

| Factor | Why clinicians care | What readers must not do | |--------|---------------------|---------------------------| | CYP2D6 poor metabolizer genotype | May clear ibogaine differently; higher parent exposure risk themes | Self-dose from 23andMe screenshots | | Strong CYP2D6 inhibitors (e.g., some SSRIs such as paroxetine/fluoxetine in classic teaching) | Can phenoconvert toward poorer metabolism | Stop antidepressants from a blog | | Unknown product potency (gray market) | Exposure unknowable | Buy “genotyped microdose kits” |

Microdosing myths: /blog/ibogaine-microdosing-myths.

Does IV psychoactive dosing erase CYP2D6 issues?

No. Changing route changes absorption kinetics; it does not delete hepatic/intestinal enzyme biology, metabolite formation, or the need for medication review. Controlled psychoactive-IV PK evidence remains sparse relative to oral papers. Oral vs IV: /blog/ibogaine-oral-vs-iv.

Support IV magnesium (as in MISTIC) is support, not a CYP2D6 bypass (/blog/stanford-ibogaine-mistic · /blog/electrolytes-support-iv-vs-psychoactive-iv).

How ethical IV programs use metabolism literacy

Expect (themes):

• Full medication/supplement reconciliation
• Discussion of known CYP2D6 inhibitors/substrates on your list
• ECG/electrolytes and continuous monitoring plans
• Possible research-minded interest in genotyping—never sold as a cure predictor
• Willingness to say no

Entity/process: /what-is-ibogaine-infusion · /how-it-works · /safety-and-screening · Session map: /blog/what-to-expect-iv-ibogaine-session.

Red flags

1. “We genotype so cardiac risk is gone”
2. DIY dose apps based on Ancestry/23andMe uploads
3. Citing Glue’s 20 mg volunteer study as proof a flood is safe
4. Claiming MISTIC IV-Mg proves metabolism problems solved
5. Selling noribogaine capsules as “safer CYP2D6-proof ibogaine”

Clinic vetting: /blog/how-to-choose-an-ibogaine-clinic · /blog/cheap-ibogaine-clinic-red-flags.

Legal / geography

Ibogaine is U.S. Schedule I / not FDA-approved (/blog/is-ibogaine-legal-us). Provisional Mexico programs discussed on this site ≠ FDA/US clinics (/blog/ibogaine-mexico-medical-vs-tourism). Genotype reports do not legalize possession.

Condition pages (no cures): /ibogaine-for-addiction · /ibogaine-for-depression · /ibogaine-for-ptsd.

Noribogaine persistence and why “parent cleared = safe” fails

Even when parent ibogaine levels fall, noribogaine can remain relevant in clinical toxicology narratives and prolonged monitoring discussions. Consumers sometimes hear “your ibogaine is gone, go hotel.” Medical-model care treats observation windows as clinician-owned, not influencer-owned.

Related: /blog/ibogaine-side-effects · /blog/what-to-expect-iv-ibogaine-session · aftercare /blog/ibogaine-aftercare-integration.

Practical applicant checklist (metabolism literacy)

1. Export a complete Rx + OTC + supplement list before screening.
2. Flag known CYP2D6 inhibitors/substrates for the clinician—do not self-stop.
3. Ask whether the program’s psychoactive route is oral or IV in writing.
4. Ask how QTc monitoring duration is chosen.
5. Refuse vendors selling genotype-based DIY flood calculators.

Consent twin: /blog/ibogaine-informed-consent-questions · clinic choice: /blog/how-to-choose-an-ibogaine-clinic · cost: /blog/cost-of-ibogaine-treatment.

Research vs consumer access

State bills, IND headlines, and noribogaine development news may mention metabolism science. Landscape only: research interest ≠ walk-in FDA clinic (/blog/ibogaine-state-research-bills-2026 · /blog/is-ibogaine-legal-us).

Soft CTA

Metabolism curiosity should lead to screening—not spreadsheet dosing. Read /safety-and-screening, then request a confidential screening consult via /apply. FAQ: /faq · Consent: /blog/ibogaine-informed-consent-questions.

FAQ

What enzyme metabolizes ibogaine? CYP2D6 is the primary enzyme for O-demethylation to noribogaine, per foundational metabolism work.

Do poor metabolizers face different risks? Exposure can differ; clinicians may discuss genotyping and inhibitors. Not a DIY risk calculator.

Is the key PK evidence oral? Yes. Major human PK papers describe oral dosing; psychoactive-IV controlled evidence is sparse.

Does IV magnesium fix CYP2D6 issues? No. In MISTIC, IV magnesium was support alongside **oral** ibogaine.

Should I stop paroxetine before ibogaine? Do not change psychiatric medicines from a blog. Ask licensed clinicians.

Is genotyping required for treatment? Not an FDA-label requirement (there is no FDA-approved ibogaine treatment). Some research discussions encourage it; it is not a cure tool.

Does metabolism science prove ibogaine cures addiction? No. No cure claims.

Where should I go next? /safety-and-screening then /apply.

Medical disclaimer

Educational pharmacology literacy only—not a dosing protocol, genotyping service, medical advice, or legal advice. Do not self-administer ibogaine. Do not alter prescriptions without licensed clinicians. Cardiac events can be life-threatening.

Sources (selected)

1. Obach R.S., Pablo J., Mash D.C. — CYP2D6 catalyzes O-demethylation of ibogaine to 12-hydroxyibogamine (noribogaine).
2. Glue P. et al. *Journal of Clinical Pharmacology* — CYP2D6 activity influences PK/PD after oral 20 mg ibogaine.
3. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; QTc findings.
4. Related OUD PK/PD analyses linking CYP2D6 activity to clearance and QTc discussions (oral treatment-dose contexts).
5. Cherian K.N. et al. *Nature Medicine*. 2024 — oral ibogaine + IV magnesium (MISTIC).
6. 21 CFR 1308.11 — Schedule I (ibogaine).